Cardiology Department, Parc de Salut Mar, Barcelona, Spain; Medicine Department, Autonomous University of Barcelona, Barcelona, Spain; Inflammatory and Cardiovascular Disease Programme (RICAD), IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain.
Inflammatory and Cardiovascular Disease Programme (RICAD), IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Cardiovascular and Genetic Epidemiology Research Group (EGEC, REGICOR Study Group), IMIM, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Spain.
Atherosclerosis. 2014 Jan;232(1):134-40. doi: 10.1016/j.atherosclerosis.2013.10.026. Epub 2013 Nov 7.
To assess 1) the association of lipid oxidation biomarkers with 10-year coronary artery disease (CAD) events and subclinical atherosclerosis, and 2) the reclassification capacity of these biomarkers over Framingham-derived CAD risk functions, in a general population.
Within the framework of the REGICOR study, 4782 individuals aged between 25 and 74 years were recruited in a population-based cohort study. Follow-up of the 4042 who met the eligibility criteria was carried out. Plasma, circulating oxidized low-density lipoprotein (oxLDL) and oxLDL antibodies (OLAB) were measured in a random sample of 2793 participants. End-points included fatal and non-fatal acute myocardial infarction (AMI) and angina. Carotid intima-media thickness (IMT) in the highest quintile and ankle-brachial index <0.9 were considered indicators of subclinical atherosclerosis.
Mean age was 50.0 (13.4) years, and 52.4% were women. There were 103 CAD events (34 myocardial infarction, 43 angina, 26 coronary deaths), and 306 subclinical atherosclerosis cases. Oxidized LDL was independently associated with higher incidence of CAD events (HR = 1.70; 95% Confidence Interval: 1.02-2.84), but not with subclinical atherosclerosis. The net classification index of the Framingham-derived CAD risk function was significantly improved when ox-LDL was included (NRI = 14.67% [4.90; 24.45], P = 0.003). No associations were found between OLAB and clinical or subclinical events. The reference values for oxLDL and OLAB are also provided (percentiles).
OxLDL was independently associated with 10-year CAD events but not subclinical atherosclerosis in a general population, and improved the reclassification capacity of Framingham-derived CAD risk functions.
评估 1)脂质氧化生物标志物与 10 年冠心病 (CAD) 事件和亚临床动脉粥样硬化的关联,以及 2)这些生物标志物在一般人群中对Framingham 衍生 CAD 风险函数的重新分类能力。
在 REGICOR 研究框架内,在一项基于人群的队列研究中招募了 4782 名年龄在 25 至 74 岁之间的个体。对符合入选标准的 4042 名个体进行了随访。在 2793 名随机样本参与者中测量了血浆、循环氧化低密度脂蛋白 (oxLDL) 和 oxLDL 抗体 (OLAB)。终点包括致命性和非致命性急性心肌梗死 (AMI) 和心绞痛。颈动脉内膜中层厚度 (IMT) 最高五分位数和踝臂指数 <0.9 被认为是亚临床动脉粥样硬化的指标。
平均年龄为 50.0(13.4)岁,52.4%为女性。发生了 103 例 CAD 事件 (34 例心肌梗死、43 例心绞痛、26 例冠状动脉死亡) 和 306 例亚临床动脉粥样硬化病例。氧化 LDL 与 CAD 事件发生率升高独立相关 (HR = 1.70;95%置信区间:1.02-2.84),但与亚临床动脉粥样硬化无关。当纳入 ox-LDL 时,Framingham 衍生 CAD 风险函数的净分类指数显著改善 (NRI = 14.67%[4.90;24.45],P = 0.003)。OLAB 与临床或亚临床事件之间未发现关联。还提供了 oxLDL 和 OLAB 的参考值 (百分位数)。
在一般人群中,氧化 LDL 与 10 年 CAD 事件独立相关,但与亚临床动脉粥样硬化无关,并改善了Framingham 衍生 CAD 风险函数的重新分类能力。